Revumenib,2169919-21-3

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Revumenib

CAS No. : 2169919-21-3

MCE 国际站：Revumenib

产品活性：Revumenib (SNDX-5613) 是一种有效的特异性 Menin-MLL 抑制剂，结合 K_i 为 0.149 nM，细胞实验中，抑制 Menin-MLL 的 IC₅₀ 为 10-20 nM。Revumenib 可用于 MLL 基因重排的急性白血病研究，包括急性淋巴细胞白血病 (ALL) 和急性髓细胞白血病 (AML)。

研究领域：Epigenetics

作用靶点：Epigenetic Reader Domain

In Vivo: Revumenib (SNDX-5613) shows in vivo plasma IC₅₀ of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Epigenetics Compound Library  |  Histone Modification Research Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Reprogramming Compound Library  |  Anti-Blood Cancer Compound Library  |  Targeted Diversity Library  |  Protein-protein Interaction Inhibitor Library  |  Heterocyclic Compound Library  |  Highly Selective Inhibitors Library  |  (+)-JQ-1  |  Curcumin  |  A-485  |  C646  |  BRM/BRG1 ATP Inhibitor-1  |  BI 2536  |  dBET6  |  MZ 1  |  ARV-825  |  Inobrodib  |  Birabresib  |  666-15  |  SGC-CBP30  |  VTP50469  |  ACBI1  |  AU-15330  |  ARV-771  |  I-BET151  |  dBET1  |  dCBP-1  |  ABBV-744  |  Anacardic Acid  |  Molibresib  |  NSC 228155  |  KG-501  |  A-366  |  FHD-286  |  Mivebresib  |  MG 149

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds